Lesinurad for the treatment of hyperuricaemia in people with gout

References

• Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017 Jan;76(1):29–42.
   PubMed Web of Science ®Google Scholar
• Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431–1446.
   PubMed Web of Science ®Google Scholar
• Gibson T, Highton J, Potter C, et al. Renal impairment and gout. Ann Rheum Dis. 1980 Oct;39(5):417–423.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Calabozo M, Erauskin GG, et al. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum. 2002 Dec 15;47(6):610–613.
   PubMedGoogle Scholar
• Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002 May 23;417(6887):447–452.
   PubMed Web of Science ®Google Scholar
• Miner J, Pk T, Hyndman D, et al. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther. 2016 Oct 03;18(1):214.
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services Food and Drug Administration. FDA Briefing Package. NDA 207988: lesinurad for the proposed indication of treatment of hyperuricemia associated with gout in combination with a xanthine oxidase inhibitor. Department of Health and Human Services. 2015.
   Google Scholar
• U.S. Food and Drug Administration. [cited 2017 Sep 6]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209203.
   Google Scholar
• Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the national health and nutrition examination survey 2007-2008. Arthritis Rheum. 2011 Oct;63(10):3136–3141.
   PubMed Web of Science ®Google Scholar
• Robinson PC, Taylor WJ, An Observational DN. Study of gout prevalence and quality of care in a National Australian General Practice Population. J Rheumatol. 2015 Sep;42(9):1702–1707.
   PubMed Web of Science ®Google Scholar
• Singh JA, Akhras KS, Shiozawa A. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Res Ther. 2015 May;12(17):120.
   Google Scholar
• Becker MA, Schumacher HR Jr., Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005 Dec 08;353(23):2450–2461.
   PubMed Web of Science ®Google Scholar
• Krishnan E, Chen L. Trends in physician diagnosed gout and gout therapies in the US: results from the national ambulatory health care surveys 1993 to 2009. Arthritis Res Ther. 2013 Nov 06;15(6):R181.
   PubMed Web of Science ®Google Scholar
• Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. Jama. 2011 Aug 17;306(7):711–720.
   PubMed Web of Science ®Google Scholar
• Lipsky PE, Calabrese LH, Kavanaugh A, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014 Mar 04;16(2):R60.
   PubMed Web of Science ®Google Scholar
• Shen Z, Gillen M, Miner JN, et al. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects. Drug Des Devel Ther. 2017;11:2077–2086.
   PubMed Web of Science ®Google Scholar
• Steinberg AS, Vince BD, Choi YJ, et al. Pharmacokinetics, and safety of arhalofenate in combination with febuxostat when treating hyperuricemia associated with gout. J Rheumatol. 2017 Mar;44(3):374–379.
   PubMed Web of Science ®Google Scholar
• Cartwright H. AstraZeneca looks to replenish late-stage pipeline with US$1.26 B ardea biosciences acquisition. PharmaDeals Rev. 2012;2012(4):62.
   Google Scholar
• Shen Z, Rowlings C, Kerr B, et al. Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males. Drug Des Devel Ther. 2015;9:3423–3434.
   PubMed Web of Science ®Google Scholar
• Gillen M, Valdez S, Zhou D, et al. Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers. Drug Des Devel Ther. 2016;10:3555–3562.
   PubMed Web of Science ®Google Scholar
• Gillen M, Yang C, Wilson D, et al. Evaluation of pharmacokinetic interactions between lesinurad, a new selective urate reabsorption inhibitor, and CYP enzyme substrates sildenafil, amlodipine, tolbutamide, and repaglinide. Clin Pharmacol Drug Dev. 2017 Jul;6(4):363–376.
   PubMed Web of Science ®Google Scholar
• Shen Z, Tieu K, Wilson D, et al. Evaluation of pharmacokinetic interactions between lesinurad, a new selective urate reabsorption inhibitor, and commonly used drugs for gout treatment. Clin Pharmacol Drug Dev. 2017 Jul;6(4):377–387.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Kerr B, Yeh LT, et al. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Rheumatology. 2014 Dec;53(12):2167–2174.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Sundy JS, Miner JN, et al. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis. 2016 Jun;75(6):1074–1080.
   PubMed Web of Science ®Google Scholar
• Saag KG, Fitz-Patrick D, Kopicko J, et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-Based Study). Arthritis Rheumatol. 2017 Jan;69(1):203–212.
   PubMed Web of Science ®Google Scholar
• Bardin T, Keenan RT, Khanna PP, et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis. 2017 May;76(5):811–820.
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Jones G, Terkeltaub R, et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial. Arthritis Rheumatol. 2017 Sep;69(9):1903–1913.
   PubMed Web of Science ®Google Scholar
• Tausche AK, Alten R, Dalbeth N, et al. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study. Rheumatology. 2017 Sep;23 . doi: 10.1093/rheumatology/kex350. [ Epub ahead of print].
   Google Scholar
• Stamp LK, Chapman PT, Barclay ML, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis. 2017 Sep;76(9):1522–1528.
   PubMed Web of Science ®Google Scholar
• Stamp LK, Chapman PT, Barclay M, et al. Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study. Ann Rheum Dis. 2017 Aug 22. Epub ahead of print.
   Google Scholar
• Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis. 2012 Sep;71(9):1490–1495.
   PubMed Web of Science ®Google Scholar
• Reinders MK, Van Roon EN, Houtman PM, et al. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol. 2007 Sep;26(9):1459–1465.
   PubMed Web of Science ®Google Scholar
• Pui K, Gow PJ, Dalbeth N. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. J Rheumatol. 2013 Jun;40(6):872–876.
   PubMed Web of Science ®Google Scholar